Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
PRNewsWire
·
2026-05-18
·
via The Tech Buzz - Press Releases
Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。